Net profit of Artgen Biotech (formerly ISKCH) under IFRS for 2023 increased 8 times to 194.66 million rubles from 23.07 million rubles a year earlier. Revenue increased by 20.4% to RUB 1.37 billion from RUB 1.13 billion, and operating expenses increased by 6.5%. Operating profit amounted to RUB 275.5 million against RUB 110.9 million. EBITDA increased to RUB 299.19 million from RUB 138.12 million. This is stated in the company's message.
Artgen Biotech is a biotechnology company. The Artgen Biotech group includes companies at different stages of development – from the seed stage to the stage of early growth and maturity, as well as companies that form an ecosystem for accelerating biotech developments in the group.
Consolidated revenue of PJSC Artgen Biotech for 9 months of 2023 according to IFRS increased by 18% and amounted to about 1 billion rubles (963.97 million rubles against 817,888 million rubles) Operating profit increased by 92% and amounted to 147.27 million rubles. Compared to RUB 76.72 million, EBITDA increased by 68% and amounted to about RUB 210 million.
Artgen Biotech's RAS net profit for 2023 increased by 17.8% to RUB 244.62 million from RUB 207.6 million a year earlier. Revenue decreased by 8% to 74.14 million rubles from 80.58 million rubles. Gross profit increased by 51.5% to RUB 21.217 million from RUB 14 million. Income from participation in other organizations amounted to 308.58 million rubles (+29.8%).
